Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Invivyd Inc. (IVVD:NASDAQ), powered by AI.
Invivyd Inc. is currently trading at $1.78. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Invivyd Inc. on Alpha Lenz.
Invivyd Inc.'s P/E ratio is -1.2.
“Invivyd Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -138.7%.”
Ask for details →Invivyd Inc. is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies to address significant unmet medical needs. Central to Invivyd's mission is its dedication to creating antibody therapies that provide potent and durable protection against a range of infectious diseases. Operating within the biotechnology sector, the company employs advanced research methodologies and cutting-edge technologies to develop its pipeline of therapeutic solutions. Invivyd Inc. is strategically positioned to impact healthcare by advancing treatments that could improve patient outcomes for diseases that currently have limited or inadequate therapeutic options. By pursuing novel antibody candidates, Invivyd plays a crucial role in public health and pharmaceutical innovation, contributing to enhanced management and prevention strategies across global healthcare markets. Its efforts reflect the growing importance of biotechnology in addressing modern healthcare challenges.
“Invivyd Inc. trades at a P/E of -1.2 (undervalued) with modest ROE of -138.7%.”
Ask for details →Invivyd Inc. (ticker: IVVD) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 99 employees. Market cap is $211M.
The current price is $1.78 with a P/E ratio of -1.24x and P/B of 3.12x.
ROE is -138.71% and operating margin is -696.80%. Annual revenue is $25M.